# Mediwheel <wellness@mediwheel.in>

Mon 3/18/2024 5:36 PM

To:PHC [MH-Ghaziabad] <phc.ghaziabad@manipalhospitals.com> Cc:customercare@mediwheel.in <customercare@mediwheel.in>



011-41195959

# Hi Manipal Hospital,

The following booking has been confirmed. It is requested to honor the said booking & provide priority services to our client

Hospital

Package Name

: Mediwheel Full Body Health Checkup Male Above 40

Patient Package

Name

: MediWheel Full Body Health Checkup Male 40 To 50

Contact Details : 9910750747

Appointment

Date

: 19-03-2024

Confirmation

Status

: Booking Confirmed

**Preferred Time** 

: 8:30am

Pooled M. J. N.	Member Information	
Booked Member Name KAPIL KUMAR	Age	Gender
TOTAL KUWAK	44 year	Male

We request you to facilitate the employee on priority.

Thanks, Mediwheel Team Please Download Mediwheel App





You have received this mail because your e-mail ID is registered with Arcofemi Healthcare Limited This is a system-generated e-mail please don't reply to this

Please visit to our Terms & Conditions for more information. Click here to unsubscribe.

@ 2024 - 25, Arcofemi Healthcare Pvt Limited.(Mediwheel)

Favórites -

Health checkup at tie-up Ctr

HealthChkup Authorisatn letter



Union Bank of India

RO - GHAZIABAD GHAZIABAD,, GHAZIABAD,, Uttar Pradesh, - 0

To,

The Chief Medical Officer

M/S Mediwheel https://mediwheel.in/signup011-41195959(A brand name of Arcofemi Healthcare Ltd), Mumbai400021

Dear Sir,

Tie-up arrangement for Health Checkup under Health Checkup

40°-50 Male

Shri/Smt./Kum.

P.F. No.

KAPIL KUMAR,.

Checkup for Financial Year

63507

Approved Charges Rs. 2023-

3500.00

. 2024 . The above mentioned staff member of our Branch/Office desires to undergo Health Checkup at your Hospital/Centre/Clinic, under the tie-up arrangement entered into with you, by our bank.

Please send the receipt of the above payment and the relevant reports to our above address.

Thanking you

Yours Faithfully,

(Signature of the Employee)

BRANCH MANAGER/SENIOR MANAGER

PS. : Status of the application-



# Indian Union Driving Licence Issued by Uttar Pradesh







Issue Date Validity (NT) 26-11-2022 25-11-2032

Validity(TR)\*



Name:

KAPIL KUMAR

Blood Group: Date of Birth: 07-07-1979

Son/Daughter/Wife of: NAWAB SINGH

Organ Donor: N

(26-11-2022) Date of First Issue

Address: House Number -330 Vivekanand Nagar Ghaziabad Ghaziabad Uttar Pradesh 201002

DL No: UP14 20220067754

UPDL000009739789



Invalid Carriage (Regn Numbers)#

Hazardous Validity\*

Hill Validity\*

Code	Issued By	Date of Issue	Vehicle Category	Badge Number	Badge Issued Date*	Badge Issued By
MCWG	UP14	26-11-2022	NT			
LMV	UP14	26-11-2022	NT			
				0	-1	
	MCWG	MCWG UP14	Code   Issued By   Issue	Code Issued By Issue Category MCWG UP14 26-11-2022 NT	Code         Issued By         Issue         Category         Number*           MCWG         UP14         26-11-2022         NT	Code         Issued By         Issue         Category         Number*         Issued Date*           MCWG         UP14         26-11-2022         NT         Issued Date*









Ph. +91 120 353 5353, M. 88609 45566 Www.manipalhospitals.com

# **LABORATORY REPORT**

Name

: MR KAPIL KUMAR

Registration No

: MH011784990

Patient Episode

: H18000001943

This report is subject

Referred By

: HEALTH CHECK MGD

Receiving Date

: 19 Mar 2024 09:03

Age

40 Yr(s) Sex :Male

Lab No

202403002787

**Collection Date:** 

19 Mar 2024 09:03

Reporting Date:

19 Mar 2024 12:13

#### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

#### GLUCOSE-Fasting

Specimen: Plasma

GLUCOSE, FASTING (F)

Method: Hexokinase

110.0

mg/dl

[70.0-110.0]

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%). Drugs corticosteroids, phenytoin, estrogen, thiazides

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortica insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibro sarcoma), infant of a diabetic mother enzyme deficiency diseases(e.g.galactosemia), orugs-

insulin, ethanol, propranolol, sulfonylureas, tobutamide, and other oral hypoglycemic agents.

Page 1 of 2

-----END OF REPORT-----

Dr. Charu Agarwal Consultant Pathologist





Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

LABORATORY REPORT

Name

: MR KAPIL KUMAR

Registration No

: MH011784990

Patient Episode

: H18000001943

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

: 19 Mar 2024 12:35

Age

40 Yr(s) Sex :Male

Lab No

202403002788

Collection Date:

19 Mar 2024 12:35

Reporting Date:

19 Mar 2024 13:57

**BIOCHEMISTRY** 

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

PLASMA GLUCOSE

Specimen:Plasma

GLUCOSE, POST PRANDIAL (PP), 2 HOURS

169.0 #

mg/dl

[80.0-140.0]

Method: Hexokinase

Note:

Conditions which can lead to lower postprandial glucose levels as compared to fasting glucose are excessive insulin release, rapid gastric emptying, brisk glucose absorption , post exercise

Page 2 of 2

----END OF REPORT--

Dr. Charu Agarwal Consultant Pathologist







Name

: MR KAPIL KUMAR

Registration No

: MH011784990

Patient Episode

: H18000001943

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

: 19 Mar 2024 09:03

Age

40 Yr(s) Sex :Male

Lab No

202403002786

**Collection Date:** 

19 Mar 2024 09:03

**Reporting Date:** 

19 Mar 2024 11:23

# HAEMATOLOGY

7	ľ	76	3"	Г
-	-	-	,	-

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

COMPLETE BLOOD COUNT (AUTOMATE	D)	SPECIMEN-EDTA Whole	Blood	
RBC COUNT (IMPEDENCE) HEMOGLOBIN Method:cyanide free SLS-colori	<b>5.61 #</b> 15.5 metry	millions/cumm g/dl	[ <b>4.50-5.50</b> ] [13.0-17.0]	
HEMATOCRIT (CALCULATED) MCV (DERIVED) MCH (CALCULATED) MCHC (CALCULATED) RDW CV% (DERIVED) Platelet count Method: Electrical Impedance MPV (DERIVED)	47.4 84.5 27.6 32.7 <b>14.1</b> # 245	fL pg g/dl % x 10 <sup>3</sup> cells/cumm	[40.0-50.0] [83.0-101.0] [25.0-32.0] [31.5-34.5] [11.6-14.0] [150-410]	
WBC COUNT(TC)(IMPEDENCE) DIFFERENTIAL COUNT (VCS TECHNOLOGY/MICROSCOPY)	7.13	x 10³ cells/cumm	[4.00-10.00]	
Neutrophils Lymphocytes Monocytes Eosinophils Basophils	42.0 <b>43.0 #</b> 9.0 6.0 0.0	96 96 90 90 90	[40.0-80.0] [20.0-40.0] [2.0-10.0] [1.0-6.0] [0.0-2.0]	
ESR	7.0	mm/1sthour	[0.0-	

Page1 of 8







Name

: MR KAPIL KUMAR

**Registration No Patient Episode**  : MH011784990 : H18000001943

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

**TEST** 

ESR

: 19 Mar 2024 09:03

Age

40 Yr(s) Sex: Male

Lab No

202403002786

**Collection Date:** 

19 Mar 2024 09:03

Reporting Date:

19 Mar 2024 11:23

BIOLOGICAL REFERENCE INTERVAL

### HAEMATOLOGY

UNIT

mm/1sthour

RESULT

7.0

COMPLETE BLOOD COUNT (AUTOMA	TED)	SPECIMEN-EDTA Whole	Blood
RBC COUNT (IMPEDENCE)	5.61 #	millions/cumm	[4.50-5.50]
HEMOGLOBIN	15.5	g/dl	[13.0-17.0]
Method:cyanide free SLS-colo	E 17000000	97	
HEMATOCRIT (CALCULATED)	47.4	8	[40.0-50.0]
MCV (DERIVED)	84.5	fL	[83.0-101.0]
MCH (CALCULATED)	27.6	pg	[25.0-32.0]
MCHC (CALCULATED)	32.7	g/dl	[31.5-34.5]
RDW CV% (DERIVED)	14.1 #	8	[11.6-14.0]
Platelet count	245	$\times$ 10 $^{3}$ cells/cumm	[150-410]
Method: Electrical Impedance			•
MPV (DERIVED)	11	fL	
LIDG COLUMN (MG) (ALICE - LICE)		9	
WBC COUNT (TC) (IMPEDENCE)	7.13	$\times$ 10 $^{3}$ cells/cumm	[4.00-10.00]
DIFFERENTIAL COUNT			
(VCS TECHNOLOGY/MICROSCOPY)			
Neutrophils	42.0	8	[40.0-80.0]
Lymphocytes	43.0 #	8	[20.0-40.0]
Monocytes	9.0	96	[2.0-10.0]
Eosinophils	6.0	96	[1.0-6.0]
Basophils	0.0	9	[0.0-2.0]

Page1 of 8

-0.0]







Name

: MR KAPIL KUMAR

Age

40 Yr(s) Sex: Male

**Registration No** 

: MH011784990

Lab No

202403002786

Patient Episode

: H18000001943

**Collection Date:** 

19 Mar 2024 10:07

Referred By

: HEALTH CHECK MGD

**Reporting Date:** 

19 Mar 2024 16:48

**Receiving Date** 

: 19 Mar 2024 10:07

#### **CLINICAL PATHOLOGY**

#### ROUTINE URINE ANALYSIS (Semi Automated) Specimen-Urine

#### MACROSCOPIC DESCRIPTION

Colour

PALE YELLOW

(Pale Yellow - Yellow)

Appearance

CLEAR

(4.6 - 8.0)

Reaction[pH] Specific Gravity

CHEMICAL EXAMINATION

6.5 1.005

(1.003 - 1.035)

Protein/Albumin

Negative

(NEGATIVE)

Glucose

NIL

(NIL)

Ketone Bodies

Negative

(NEGATIVE)

Urobilinogen

Normal

(NORMAL)

#### MICROSCOPIC EXAMINATION (Automated/Manual)

Pus Cells

1-2 /hpf

RBC

NIL

(0-5/hpf)(0-2/hpf)

Epithelial Cells

0 - 1

NIL

/hpf

CASTS Crystals

NIL

Bacteria

NIL

OTHERS

NIL

Page 2 of 8







Name

: MR KAPIL KUMAR

Age

40 Yr(s) Sex : Male

**Registration No** 

: MH011784990

Lab No

202403002786

**Patient Episode** 

: H18000001943

**Collection Date:** 

19 Mar 2024 09:03

Referred By

: HEALTH CHECK MGD

Reporting Date:

19 Mar 2024 18:18

**Receiving Date** 

: 19 Mar 2024 09:03

### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Glycosylated Hemoglobin

Specimen: EDTA

HbA1c (Glycosylated Hemoglobin)

5.7 #

%

[0.0-5.6]

Method: HPLC

As per American Diabetes Association (ADA

HbAlc in %

Non diabetic adults >= 18years <5.7 Prediabetes (At Risk )5.7-6.4 Diagnosing Diabetes >= 6.5

Estimated Average Glucose (eAG)

117

mg/dl

Comments: HbAlc provides an index of average blood glucose levels over the past 8-12 weeks and is a much better indicator of long term glycemic control.

#### Serum LIPID PROFILE

Serum TOTAL CHOLESTEROL Method:Oxidase,esterase, peroxide	215 #	mg/dl	[<200] Moderate risk:200-239
TRIGLYCERIDES (GPO/POD)	161 #	mg/dl	High risk:>240 [ <b>&lt;150]</b>
			Borderline high:151-199 High: 200 - 499
			Very high:>500
HDL- CHOLESTEROL	67 #	mg/dl	[35-65]
Method: Enzymatic Immunoimhibition			
VLDL- CHOLESTEROL (Calculated)	32	mg/dl	[0-35]
CHOLESTEROL, LDL, CALCULATED	116.0	mg/dl	[<120.0]
			Near/

Above optimal-100-129

Borderline High:130-159 High Risk:160-189

Page 3 of 8







Name

: MR KAPIL KUMAR

Age

40 Yr(s) Sex :Male

Registration No

: MH011784990

Lab No

202403002786

Patient Episode

: H18000001943

**Collection Date:** 

19 Mar 2024 09:03

Referred By

: HEALTH CHECK MGD

Reporting Date:

19 Mar 2024 12:12

**Receiving Date** 

: 19 Mar 2024 09:03

#### **BIOCHEMISTRY**

TEST	RESULT		UNIT	BIOLOGICAL REFERENCE INTERVAL
T.Chol/HDL.Chol ratio(Calcu	lated)	3.2	ii e	<4.0 Optimal 4.0-5.0 Borderline
LDL.CHOL/HDL.CHOL Ratio(Calc	ulated)	1.7	-	>6 High Risk <3 Optimal 3-4 Borderline >6 High Risk

#### Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis and other diseases

#### KIDNEY PROFILE

Specimen: Serum			
UREA	21.1	mg/dl	[15.0-40.0]
Method: GLDH, Kinatic assay BUN, BLOOD UREA NITROGEN	9.9	mg/dl	[8.0-20.0]
Method: Calculated	9.9	mg/ dr	[0.0 20.0]
CREATININE, SERUM	0.71	mg/dl	[0.70-1.20]
Method: Jaffe rate-IDMS Standardization		1 8	1100 0 0 0
URIC ACID	4.8	mg/dl	[4.0-8.5]
Method:uricase PAP	41		
SODIUM, SERUM	136.40	mmol/L	[136.00-144.00]
POTASSIUM, SERUM	4.45	mmol/L	[3.60-5.10]
SERUM CHLORIDE	102.2	mmol/L	[101.0-111.0]
Method: ISE Indirect			

Page 4 of 8







Name

: MR KAPIL KUMAR

:

: MH011784990

Registration No Patient Episode

: H18000001943

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

: 19 Mar 2024 09:03

Age

40 Yr(s) Sex :Male

Lab No

202403002786

**Collection Date:** 

19 Mar 2024 09:03

**Reporting Date:** 

19 Mar 2024 12:12

#### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

eGFR (calculated)

117 /

ml/min/1.73sq.m

CO 01

Technical Note

eGFR which is primarily based on Serum Creatinine is a derivation of CKD-EPI 2009 equation normalized to1.73 sq.m BSA and is not applicable to individuals below 18 years. eGFR tends to be less accurate when Serum Creatinine estimation is indeterminate e.g. patients at extremes of muscle mass, on unusual diets etc. and samples with severe Hemolysis Icterus / Lipemia.

#### LIVER FUNCTION TEST

AST(SGOT) (SERUM) Method: IFCC W/O P5P	53.00 #	U/L	[0.00-40.00]
PROTEIN SERUM (A-G) RATIO Method: Calculation	1.39		[1.00-2.50]
GLOBULINS (SERUM) Method: Calculation	3.20	gm/dl	[1.80-3.40]
ALBUMIN (SERUM) Method: BCG	4.48	g/dl	[3.50-5.20]
TOTAL PROTEINS (SERUM) Method: BIURET	7.70	gm/dl	[6.60-8.70]
INDIRECT BILIRUBIN (SERUM) Method: Calculation	0.84	mg/dl	[0.10-0.90]
BILIRUBIN - DIRECT Method: DPD	0.21	mg/dl	[0.00-0.30]
BILIRUBIN - TOTAL Method: D P D	1.05	mg/dl	[0.30-1.20]

Page 5 of 8





# LABORATORY REPORT

Name

MR KAPIL KUMAR

Age

40 Yr(s) Sex: Male

**Registration No** 

MH011784990

Lab No

202403002786

**Patient Episode** 

H18000001943

**Collection Date:** 

19 Mar 2024 09:03

Referred By

HEALTH CHECK MGD

**Reporting Date:** 

19 Mar 2024 16:36

**Receiving Date** 

19 Mar 2024 09:03

#### **BIOCHEMISTRY**

TEST

RESULT

UNIT

**BIOLOGICAL REFERENCE INTERVAL** 

Specimen Type : Serum

#### THYROID PROFILE, Serum

T3 - Triiodothyronine (ELFA)	1.220	ng/ml	[0.610-1.630]
T4 - Thyroxine (ELFA)	6.070	ug/ dl	[4.680-9.360]
Thyroid Stimulating Hormone	2.150	μIU/mL	[0.250-5.000]

#### NOTE:

TSH stimulates the thyroid gland to produce the main thyroid hormones T3 and T4. In cases of hyperthyroidism TSH level is severely inhibited and may even be undetectable. In rare forms of high-origin hyperthyroidism, the TSH level is not reduced, since the negative-feedback control of the thyroid hormones has no effect.

In cases of primary hypothyroidism, TSH levels are always much higher than normal and thyroid hormone levels are low.

The TSH assay aids in diagnosing thyroid or hypophysial disorders.

The T4 assay aids in assessing thyroid function, which is characterized by a decrease in thyroxine levels in patients with hypothyroidism and an increase in patients with hyperthyroidism.

The test has been carried out in Fully Automated Immunoassay System VIDAS using ELFA (Enzyme Linked Fluorescence Assay) technology.

Page 1 of 3





Name

: MR KAPIL KUMAR

Age

40 Yr(s) Sex :Male

Registration No

: MH011784990

Lab No

202403002786

Patient Episode

H18000001943

**Collection Date:** 

19 Mar 2024 09:03

Referred By

HEALTH CHECK MGD

Reporting Date:

19 Mar 2024 12:13

**Receiving Date** 

: 19 Mar 2024 09:03

#### BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Specimen Type : Serum

PROSTATE SPECIFIC ANTIGEN (PSA-Total):

0.960

ng/mL

[<2.000]

Method : ELFA

Note:1.This is a recommended test for detection of prostate cancer along with Digital Recta Examination (DRE) in males above 50 years of age

damage caused by BPH, prostatitis, or prostate cancer may increase circulating PSA levels.

- 2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
- 3. PSA levels may appear consistently elevated / depressed due to the interference by hetero antibodies & nonspecific protein binding
- 4. Immediate PSA testing following digital rectal examination, ejaculation, prostatic massag indwelling catheterization, and ultrasonography and needle biopsy of prostate is not recomme as they falsely elevate levels
- 5. PSA values regardless of levels should not be interpreted as absolute evidence of the pre or absence of disease. All values should be correlated with clinical findings and results of other investigations
- 6. Sites of Non prostatic PSA production are breast epithelium, salivary glands, peri urethral
  - & anal glands, cells of male urethra && breast mil
  - 7. Physiological decrease in PSA level by 18% has been observed in hospitalized / sedentary patients either due to supine position or suspended sexual activity

Recommended Testing Intervals

- \* Pre-operatively (Baseline)
- \* 2-4 days post-operatively
- \* Prior to discharge from hospital
- \* Monthly follow-up if levels are high or show a rising trend

Page 2 of 3





Name

MR KAPIL KUMAR

Age

40 Yr(s) Sex: Male

**Registration No** 

MH011784990

Lab No

202403002786

**Patient Episode** 

H18000001943

**Collection Date:** 

19 Mar 2024 09:03

Referred By

HEALTH CHECK MGD

**Reporting Date:** 

19 Mar 2024 18:24

**Receiving Date** 

19 Mar 2024 09:03

#### **BLOOD BANK**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Blood Group & Rh Typing (Agglutination by gel/tube technique) Specimen-Blood

Blood Group & Rh typing

B Rh(D) Positive

#### Technical note:

ABO grouping and Rh typing is done by cell and serum grouping by microplate / gel technique.

-----END OF REPORT-----

Page 3 of 3

NOTE:

# - Abnormal Values

Dr. Alka Dixit Vats

**Consultant Pathologist** 





NAME .	MR Kapil KUMAR	STUDY DATE	19/03/2024 9:15AM
AGE / SEX	40 y / M	HOSPITAL NO.	MH011784990
ACCESSION NO.	R7081133	MODALITY	CR
REPORTED ON	19/03/2024 9:19AM	REFERRED BY	HEALTH CHECK MGD

#### XR- CHEST PA VIEW

FINDINGS:

LUNGS: Normal.

TRACHEA: Normal.

CARINA: Normal.

RIGHT AND LEFT MAIN BRONCHI: Normal.

PLEURA: Normal. HEART: Normal.

RIGHT HEART BORDER: Normal. LEFT HEART BORDER: Normal. PULMONARY BAY: Normal. PULMONARY HILA: Normal.

AORTA: Normal.

THORACIC SPINE: Normal.

OTHER VISUALIZED BONES: Normal. VISUALIZED SOFT TISSUES: Normal.

DIAPHRAGM: Normal.

VISUALIZED ABDOMEN: Normal. VISUALIZED NECK: Normal.

#### IMPRESSION:

-No significant abnormality seen.

Please correlate clinically

Dr. Prabhat Prakash Gupta MBBS, DNB, MNAMS

the fight and the Fill of the out

CONSULTANT RADIOLOGIST

\*\*\*\*\*End Of Report\*\*\*\*





		OTHEW DATE	19/03/2024 9:43AM
NIABAE	MR Kapil KUMAR	STUDY DATE	
NAME		HOSPITAL NO.	MH011784990
AGE / SEX	40 y / M		US
ACCESSION NO.	R7081134	MODALITY	
1010010001 14.0FANA	REFERRED BY	HEALTH CHECK MGD	
REPORTED ON	19/03/2024 11.23/11		

# **USG ABDOMEN & PELVIS**

LIVER: appears normal in size (measures 136 mm) and shape but shows diffuse increase in liver echotexture,

in keeping with diffuse grade II fatty infiltration. Rest normal.

SPLEEN: Spleen is normal in size (measures 82 mm), shape and echotexture. Rest normal.

PORTAL VEIN: Appears normal in size and measures 10 mm.

COMMON BILE DUCT: Appears normal in size and measures 4 mm.

IVC, HEPATIC VEINS: Normal.

BILIARY SYSTEM: Normal. GALL BLADDER: Gall bladder is well distended. Wall thickness is normal and lumen is echofree. Rest normal.

PANCREAS: Pancreas is normal in size, shape and echotexture. Rest normal.

KIDNEYS: Bilateral kidneys are normal in size, shape and echotexture. Cortico-medullary differentiation is

maintained. Rest normal.

Right Kidney: measures 116 x 45 mm. Left Kidney: measures 105 x 52 mm. PELVI-CALYCEAL SYSTEMS: Compact.

NODES: Not enlarged.

URINARY BLADDER: Urinary bladder is well distended. Wall thickness is normal and lumen is echofree. Rest FLUID: Nil significant.

PROSTATE: Prostate is normal in size, shape and echotexture. It measures 40 x 34 x 32 mm with volume 23 cc.

Rest normal.

SEMINAL VESICLES: Normal.

BOWEL: Visualized bowel loops appear normal.

#### **IMPRESSION**


-Diffuse grade II fatty infiltration in liver.

Recommend clinical correlation.

Dr. Prabhat Prakash Gupta MBBS, DNB, MNAMS

CONSULTANT RADIOLOGIST

\*\*\*\*\*End Of Report\*\*\*\*\*



# manipalhospitals





#### TMT INVESTIGATION REPORT

Patient Name MR KAPIL KUMAR

Location

: Ghaziabad

Age/Sex

: 40Year(s)/male

Visit No

: V000000001-GHZB

MRN No

MH011784990

Order Date

: 19/03/2024

Ref. Doctor : DR ABHISHEK SINGH

Report Date

: 19/03/2024

Protocol

: Bruce

**MPHR** 

: 180BPM

Duration of exercise

: 9min 26sec

85% of MPHR

: 153BPM

Reason for termination Blood Pressure (mmHg) : Baseline BP : 140/80mmHg

: THR achieved

Peak HR Achieved % Target HR

: 198BPM : 111%

Peak BP

: 160/90mmHg

METS

: 10.8METS

SGE	TIME (min)	H.R (bpm)	BP (mmHg)	SYMPTOMS	ECG CHANGES	ARRHYTHMIA
PRE- EXC.	0:00	87	140/80	Nil	No ST changes seen	Nil
STAGE 1	3:00	137	150/90	Nil	No ST changes seen	Nil
STAGE 2	3:00	168	150/90	Nil	No ST changes seen	Nil
STAGE 3	3:00	193	160/90	Nil	No ST changes seen	Nil
STAGE 4	0:26	198	160/90	Nil	No ST changes seen	Nil
RECOVERY	8:14	121	140/80	Nil	No ST changes seen	Nil

#### **COMMENTS:**

- No ST changes in base line ECG.
- No ST changes at peak stage.
- No ST changes in recovery.
- Normal chronotropic response.
- Normal blood pressure response.

#### **IMPRESSION:**

Treadmill test is negative for exercise induced reversible myocardial ischemia.

Dr. Bhupendra Singh

MD, DM (CARDIOLOGY), FACC Sr. Consultant Cardiology

Dr. Abhishek Singh MD, DNB (CARDIOLOGY), MNAMS MD

Sr.Consultant Cardiology

Cardiology Registrar

Dr. Sudhanshu Mishra

Manipal Hospital, Ghaziabad

NH - 24, Hapur Road, Ghaziabad, Uttar Pradesh - 201 002

P: 0120-3535353

Manipal Health Enterprises Private Limited

CIN: U85110KA2003PTC033055

Regd. Off. The Annexe, #98/2, Rustom Bagh, Off. HAL Airport Road, Bengaluru - 560 017

P +91 80 4936 0300 E info@manihospitals.com www.manipalhospitals.com